Although alterations to TP53 previously have been thought to be exclusively associated with advanced disease, a recent genomic profiling study of mostly primary prostate cancers demonstrated that 24% of cases had either a hetero- or homozygous copy number loss of TP53 [20]. This evidence concerns the gene TP53 and prostate cancer.